Sandoz filed an action for declaratory judgment against Novo Nordisk over a patent related to an NIDDM regimen for the treatment of type 2 diabetes. 8/17, Eastern District of Michigan, 2:2011cv13594.
Access to the full article is currently available to RPX members only. Please contact us if you need further information.
